Bicara Therapeutics
- Market cap
- 1.06B
- P/E (TTM)i
- -5.21
- P/Bi
- 2.26
- EPSi
- -2.52
- Div yieldi
- 0.00%
- 52W posi
- 13%
Anonymous reader poll. Unscientific, not investment advice.
About Bicara Therapeutics
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-?-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
- Founded
- 2018
- CEO
- Dr. Claire Mazumdar, M.B.A.,PhD
- Employees
- 103
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- bicara.com
Company profile
- Exchange
- US
- Symbol
- BCAX
- Market-cap rank
- #3193
- Listing date
- 2024-09-13
- Market cap
- 1.06B
- Float cap
- 588.20M
- Shares out
- 66.17M
- Float shares
- 36.76M
Sectors & themes
Quote time 2026-10-08 10:00:10 · For reference only, not investment advice and not tailored to your situation.